IL301406A - Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions - Google Patents

Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions

Info

Publication number
IL301406A
IL301406A IL301406A IL30140623A IL301406A IL 301406 A IL301406 A IL 301406A IL 301406 A IL301406 A IL 301406A IL 30140623 A IL30140623 A IL 30140623A IL 301406 A IL301406 A IL 301406A
Authority
IL
Israel
Prior art keywords
amino acid
seq
variant
luka
lukb
Prior art date
Application number
IL301406A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceuticals Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ New York filed Critical Janssen Pharmaceuticals Inc
Publication of IL301406A publication Critical patent/IL301406A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL301406A 2020-09-28 2021-09-28 Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions IL301406A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063084273P 2020-09-28 2020-09-28
PCT/US2021/052418 WO2022067255A2 (en) 2020-09-28 2021-09-28 Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions

Publications (1)

Publication Number Publication Date
IL301406A true IL301406A (en) 2023-05-01

Family

ID=80846955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301406A IL301406A (en) 2020-09-28 2021-09-28 Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions

Country Status (15)

Country Link
US (1) US20240050546A1 (https=)
EP (1) EP4216982A4 (https=)
JP (1) JP2023544300A (https=)
KR (1) KR20230091911A (https=)
CN (1) CN116670158A (https=)
AR (1) AR123635A1 (https=)
AU (1) AU2021350860A1 (https=)
CA (1) CA3195895A1 (https=)
CL (1) CL2023000884A1 (https=)
CO (1) CO2023004198A2 (https=)
IL (1) IL301406A (https=)
JO (1) JOP20230065A1 (https=)
MX (1) MX2023003581A (https=)
NZ (1) NZ798451A (https=)
WO (1) WO2022067255A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
EP4015523A1 (en) * 2010-05-05 2022-06-22 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
RU2016110800A (ru) * 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
EP3464349A4 (en) * 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
EP3638286A4 (en) * 2017-06-13 2021-03-10 Integrated Biotherapeutic Vaccines, Inc. IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions

Also Published As

Publication number Publication date
US20240050546A1 (en) 2024-02-15
CL2023000884A1 (es) 2023-09-29
JP2023544300A (ja) 2023-10-23
AR123635A1 (es) 2022-12-28
EP4216982A4 (en) 2025-03-19
WO2022067255A2 (en) 2022-03-31
CN116670158A (zh) 2023-08-29
JOP20230065A1 (ar) 2023-03-28
CA3195895A1 (en) 2022-03-31
AU2021350860A1 (en) 2023-05-04
EP4216982A2 (en) 2023-08-02
KR20230091911A (ko) 2023-06-23
CO2023004198A2 (es) 2023-07-31
MX2023003581A (es) 2023-06-21
WO2022067255A3 (en) 2022-04-28
NZ798451A (en) 2024-11-29

Similar Documents

Publication Publication Date Title
KR101907434B1 (ko) C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
KR102239207B1 (ko) 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
CA2857666C (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
WO2001045639A2 (en) Methods for protecting against lethal infection with bacillus anthracis
CA2825770A1 (en) Immunogenic composition comprising alpha-hemolysin oligopeptides
KR20150119110A (ko) 에이메리아에 대한 면역 반응을 증진시키거나, 에이메리아 감염을 제한하는 조성물 및 방법
JP2015505831A5 (https=)
JP2023025066A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
KR20140033127A (ko) 스트렙토코쿠스 뉴모니애에 대한 백신
US20200317759A1 (en) Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides
KR20210088535A (ko) 폐렴구균 융합 단백질 백신
WO2015165480A1 (en) Human cytomegalovirus vaccine compositions and method of producing the same
JP5922573B2 (ja) ブドウ球菌クランピング因子aの変異体を含む免疫原性組成物
US20240050546A1 (en) Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions
US20250281591A1 (en) Staphylococcus aureus vaccine compositions
CN117355328A (zh) 金黄色葡萄球菌疫苗组合物
CA3166364A1 (en) Compositions and methods for the prevention of s. aureus infection
EA049373B1 (ru) Варианты полипептидов luka и lukb staphylococcus aureus и вакцинные композиции
TW202313660A (zh) 變異的金黃色葡萄球菌LukA和LukB多肽和疫苗組合物
US11406695B2 (en) Recombinant expression of Chlamydia MOMP antigen
WO2016112065A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
WO2020078420A1 (en) Immunogenic preparations and methods against clostridium difficile infection